SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                            ____________________

                                SCHEDULE 13D

                              (Amendment No. 2)

                  Under the Securities Exchange Act of 1934


                  Medical Technology and Innovations, Inc.
                              (Name of Issuer)

                                Common Stock
                       (Title of Class of Securities)

                                 5846 2M100
                               (CUSIP Number)

                             Richard J. Emmerich
                       Global Capital Management, Inc.
                             601 Carlson Parkway
                                  Suite 200
                         Minnetonka, Minnesota 55305
                               (612) 476-7200
                (Name, Address and Telephone Number of Person
              Authorized to Receive Notices and Communications)

                              November 26, 1997
           (Date of Event Which Requires Filing of this Statement)

        If the filing person has previously filed a statement on Schedule
   13G to report the  acquisition which is the  subject of this  Schedule
   13D, and is  filing this schedule because of Rule  13d-1(b)(3) or (4),
   check the following box  [  ].

    
                       (continued on following pages) 





   CUSIP No. 5846 2M100               Schedule 13D (Amendment No. 2)

        1)   Name of Reporting Persons/S.S. or I.R.S. Identification Nos.
             of Above Persons
             Global Capital Management, Inc./FEIN 41-1625323

        2)   Check the Appropriate Box if a Member of a Group
             (a) [  ]
             (b) [  ]

        3)   SEC Use Only


        4)   Source of Funds
                  WC

        5)   Check Box if Disclosure of Legal Proceedings is Required
             Pursuant to Item 2(d) or 2(e) [  ] 

        6)   Citizenship or Place of Organization
                  Delaware

        Number of Shares Beneficially Owned by Each Reporting Person
        with:

        (7)  Sole Voting Power
                  535,367 (See Item 5)

        (8)  Shared Voting Power
                  0

        (9)  Sole Dispositive Power
                  535,367 (See Item 5)

        (10) Shared Dispositive Power
                  0

        11)  Aggregate Amount Beneficially Owned by Each Reporting Person
                  535,367 (See Item 5)

        12)  Check Box if the Aggregate Amount in Row (11) Excludes
             Certain Shares  [  ]  

        13)  Percent of Class Represented by Amount in Row (11)
                  3.3% (See Item 5)

        14)  Type of Reporting Person
                  CO




                              Page 2 of 4 Pages





                                SCHEDULE 13D
                               AMENDMENT NO. 2


             This Amendment No. 2 is being filed pursuant to Section
   13(d) of the Securities Exchange Act of 1934 and the rules and
   regulations promulgated thereunder.  This Amendment No. 2 amends and
   supplements the Statement on Schedule 13D, as amended by Amendment No.
   1 thereto (the "Schedule 13D"), relating to the common stock, no par
   value ("Common Stock"), of Medical Technology and Innovations, Inc., a
   Florida corporation (the "Issuer"), previously filed by Global Capital
   Management, Inc., a Delaware corporation ("Global").  Capitalized
   terms used and not defined herein shall have the meanings set forth in
   the Schedule 13D.

   ITEM 4.  PURPOSE OF TRANSACTION.

        Item 4 is amended by adding the following:

        The agreement in principle between Global Bermuda and Faisal
   Finance (Switzerland) SA described in Amendment No. 1 to the Schedule
   13D was not implemented.

        Global Bermuda elected not to require compliance with its
   Conversion Notice and the Issuer redeemed the 45 shares of Series A
   Preferred Stock held by Global Bermuda at $3,800 per share.  In
   connection therewith, the Issuer agreed to reduce the exercise price
   of the Warrant to $1.00 per share, and Global Bermuda and the Issuer
   executed mutual releases.  Global Bermuda received payment of the
   redemption price on November 26, 1997.

   ITEM 5.  INTEREST IN SECURITIES OF THE ISSUER.

        Items 5(a) and 5(c) are hereby amended to read as follows:

        (a)  As of the date of this Amendment No. 2, Global Capital
             Management is the beneficial owner of an aggregate of
             535,367 shares of Common Stock, consisting of the 260,138
             shares of Common Stock held by Global Bermuda and the
             275,229 shares of Common Stock underlying the Warrant.  The
             Issuer's Form 10-QSB for the quarter ended March 31, 1997
             (which appears to be the Issuer's most recently available
             filing with the Securities and Exchange Commission) stated
             that as of that date there were 15,826,000 shares of Common
             Stock outstanding.  Based on that number of shares and
             treating the shares of Common Stock underlying the Warrant
             as also being outstanding, Global Capital Management would
             be deemed to be the beneficial owner of 3.3% of the Issuer's
             outstanding Common Stock.




                              Page 3 of 4 Pages





        (c)  No transactions in Common Stock were effected by Global
             Capital Management during the sixty (60) days prior to the
             date of this Amendment.

        Item 5 is amended by adding a subsection (e) as follows:

        (e)  Global Capital Management ceased to be the beneficial owner
             of more than five percent of the Issuer's Common Stock on
             November 26, 1997.


                                  SIGNATURE

        After reasonable inquiry and to the best of my knowledge and
   belief, I certify that the information set forth in this statement is
   true, complete and correct.

   Date: December 2, 1997        GLOBAL CAPITAL MANAGEMENT, INC.



                                 By:   /s/ John D. Brandenborg
                                    -------------------------------
                                 Name:   John D. Brandenborg
                                 Title:  Vice-President




























                              Page 4 of 4 Pages